Jack Allen
Stock Analyst at Baird
(1.02)
# 2,750
Out of 4,435 analysts
33
Total ratings
37.04%
Success rate
-23.26%
Average return
Main Sectors:
Top Industries:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TIL Instil Bio | Maintains: Outperform | $54 → $32 | $10.69 | +199.35% | 7 | May 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $53.74 | -3.24% | 2 | May 9, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $63 → $77 | $52.00 | +48.08% | 4 | Feb 29, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $10 → $7 | $0.90 | +674.85% | 2 | Dec 12, 2023 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $48.98 | +71.50% | 1 | Oct 31, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $6 → $8 | $3.43 | +133.24% | 4 | Aug 15, 2023 | |
| CARM Carisma Therapeutics | Reiterates: Outperform | $10 | $1.33 | +651.88% | 2 | Jun 28, 2023 | |
| VOR Vor Biopharma | Maintains: Outperform | $38 → $22 | $1.35 | +1,529.63% | 2 | Mar 24, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $58 → $42 | $21.38 | +96.45% | 1 | Feb 24, 2023 | |
| ALLO Allogene Therapeutics | Upgrades: Outperform | $12 | $2.50 | +380.00% | 2 | Jan 6, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $5 | $1.00 | +400.00% | 1 | Nov 2, 2022 | |
| FATE Fate Therapeutics | Initiates: Neutral | $28 | $3.68 | +660.87% | 1 | Jun 3, 2022 | |
| CLLS Cellectis | Upgrades: Outperform | n/a | $2.71 | - | 2 | May 18, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.97 | - | 1 | Nov 9, 2021 | |
| VYGR Voyager Therapeutics | Upgrades: Outperform | n/a | $8.40 | - | 1 | Oct 7, 2021 |
Instil Bio
May 13, 2024
Maintains: Outperform
Price Target: $54 → $32
Current: $10.69
Upside: +199.35%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $53.74
Upside: -3.24%
Arcellx
Feb 29, 2024
Maintains: Outperform
Price Target: $63 → $77
Current: $52.00
Upside: +48.08%
bluebird bio
Dec 12, 2023
Maintains: Outperform
Price Target: $10 → $7
Current: $0.90
Upside: +674.85%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $48.98
Upside: +71.50%
Taysha Gene Therapies
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $3.43
Upside: +133.24%
Carisma Therapeutics
Jun 28, 2023
Reiterates: Outperform
Price Target: $10
Current: $1.33
Upside: +651.88%
Vor Biopharma
Mar 24, 2023
Maintains: Outperform
Price Target: $38 → $22
Current: $1.35
Upside: +1,529.63%
Intellia Therapeutics
Feb 24, 2023
Maintains: Neutral
Price Target: $58 → $42
Current: $21.38
Upside: +96.45%
Allogene Therapeutics
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $2.50
Upside: +380.00%
Lineage Cell Therapeutics
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.00
Upside: +400.00%
Fate Therapeutics
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $3.68
Upside: +660.87%
Cellectis
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.71
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.97
Upside: -
Voyager Therapeutics
Oct 7, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.40
Upside: -